κ Opioids as Potential Treatments for Stimulant Dependence

2008 ◽  
pp. 231-245
Author(s):  
Thomas E. Prisinzano ◽  
Kevin Tidgewell ◽  
Wayne W. Harding
Keyword(s):  
Stimulant Dependence

Evaluation of GABAergic Drugs in Humans for Stimulant Dependence

2005 ◽  
Author(s):  
Joshua A. Lile ◽  
William W. Stoops ◽  
Frances P. Wagner ◽  
Jamie L. Haa ◽  
Paul E. A. Glaser ◽  
...  
Keyword(s):  
Stimulant Dependence

scholarly journals Atomoxetine for amphetamine-type stimulant dependence during buprenorphine treatment: A randomized controlled trial

2018 ◽  
Vol 186 ◽  
pp. 130-137 ◽  
Author(s):  
Richard S. Schottenfeld ◽  
Marek C. Chawarski ◽  
Mehmet Sofuoglu ◽  
Weng-Tink Chooi ◽  
Norzarina M. Zaharim ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Randomized Controlled ◽  
Stimulant Dependence ◽  
Buprenorphine Treatment

Treatment of stimulant dependence

2012 ◽  
pp. 88-97
Author(s):  
Peter Tyrer ◽  
Kenneth R. Silk
Keyword(s):  
Stimulant Dependence

scholarly journals Reduced fMRI activity predicts relapse in patients recovering from stimulant dependence

2012 ◽  
Vol 35 (2) ◽  
pp. 414-428 ◽  
Author(s):  
Vincent P. Clark ◽  
Gregory K. Beatty ◽  
Robert E. Anderson ◽  
Piyadassa Kodituwakku ◽  
John P. Phillips ◽  
...  
Keyword(s):  
Stimulant Dependence

scholarly journals dACC Response to Presentation of Negative Feedback Identifies Stimulant Dependence Diagnoses and Stimulant Use Severity

2018 ◽  
Author(s):  
Eric D. Claus ◽  
Matthew S. Shane
Keyword(s):  
Negative Feedback ◽  
Clinical Relevance ◽  
Time Estimation ◽  
Error Monitoring ◽  
Neural Responses ◽  
Stimulant Use ◽  
Core Reduction ◽  
Time Estimation Task ◽  
Following Error ◽  
Stimulant Dependence

AbstractError-monitoring abnormalities in stimulant-dependent individuals (SDIs) may be due to reduced awareness of committed errors, or to reduced sensitivity upon such awareness. The distinction between these alternatives remains largely undifferentiated, but may have substantial clinical relevance. We sought to better characterize the nature, and clinical relevance, of SDIs’ error-monitoring processes by comparing carefully isolated neural responses during the presentation of negative feedback to a) stimulant dependence status and b) lifetime stimulant use. Forty-eight SDIs and twenty-three non-SDIs performed an fMRI-based time-estimation task specifically designed to isolate neural responses associated with the presentation (versus expectation) of contingent negative feedback. SDIs showed reduced dACC response compared to non-SDIs following the presentation of negative feedback, but only when error expectancies were controlled. Moreover, lifetime stimulant use correlated negatively with magnitude of dACC attenuation. While this findings was minimized after controlling for age, these results suggest that SDIs may be characterized by a core reduction in neural activity following error feedback, in the context of intact feedback expectancies. Correlations with lifetime stimulant use suggest that this neural attenuation may hold clinical significance.

scholarly journals The coupling of nicotine and stimulant craving during treatment for stimulant dependence.

2016 ◽  
Vol 84 (3) ◽  
pp. 230-237 ◽  
Author(s):  
Joshua C. Magee ◽  
Theresa Winhusen
Keyword(s):  
Stimulant Dependence

scholarly journals Pharmacotherapy for Comorbid Adult Attention-Deficit Hyperactivity Disorder and Stimulant Dependence: A Systematic Review

2020 ◽  
Vol 17 (2) ◽  
Author(s):  
Woon LS ◽  
Hazli Z ◽  
Gan LLY
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Attention Deficit ◽  
Adult Adhd ◽  
Small Sample ◽  
Retention Rates ◽  
Adhd Symptoms ◽  
Stimulant Use ◽  
Hyperactivity Disorder ◽  
Stimulant Medications ◽  
Stimulant Dependence

Comorbid adult attention-deficit hyperactivity disorder (ADHD) and stimulant dependence is widely recognized, but efficacy of pharmacotherapy in this patient population is not well established. We aimed to review whether pharmacotherapy is efficacious in reducing ADHD symptoms and stimulant use in comorbid adult ADHD and stimulant use disorder. English articles until June 2017 were systematically searched in electronic databases (MEDLINE and PsycINFO), an online clinical trials register (ClinicalTrial.gov), and through hand-search of article references. Randomized, double-blind, placebo-controlled trials that studied efficacy of pharmacotherapy in adults with comorbid ADHD and stimulant dependence were included. Two reviewers assessed studies for inclusion and extracted data; disagreements were resolved by consensus. Study outcomes included were changes in ADHD symptom severity, substance abstinence, treatment retention rates and safety. From the 1394 records identified, five trials (n=358) were included. Four studies involved methylphenidate; in another study extended-release mixed amphetamine were used. The comorbid stimulant was cocaine in three studies, and amphetamines in the rest. All were short-term studies involving predominantly young male adults conducted in outpatient settings. There is early promising but mixed evidence for therapeutic efficacy in improving ADHD symptoms. Stimulant medications did not worsen stimulant dependence or adverse effects of stimulant medications. Side effects were mild and tolerable. High attrition rates and small sample size limited the generalizability of findings. Current limited evidence suggests that stimulant treatment for comorbid adult ADHD and stimulant dependence is feasible. Welldesigned trials with adequate power are needed for more robust evidence on ADHD and stimulant use outcomes.

Sign in / Sign up

Export Citation Format

Share Document